Sign In
Buy TARS
$58.76
+1.35 (+2.35%)
At Close: Jun 03, 2026
Why Shares of Tarsus Pharmaceuticals Are Up Thursday
02:04pm, Thursday, 20'th Jul 2023
Tarsus specializes in treating eye and skin disorders. The company is still in the clinical stage but has several late-stage pipeline candidates.
Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains?
06:08am, Thursday, 20'th Jul 2023
Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further
IRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre
Tarsus to Present at the Jefferies Global Healthcare Conference
08:30am, Monday, 05'th Jun 2023
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre
Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock?
07:38am, Tuesday, 18'th Apr 2023
Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there coul
Tarsus to Present at Upcoming Investor Conferences
04:30pm, Thursday, 02'nd Mar 2023
IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr
Tarsus Pharma: Excellent Data, Nice Execution, Unclear Market Potential
02:02pm, Tuesday, 24'th Jan 2023
Tarsus ran two pivotal trials in an eye indication. Data was excellent and shows that TP-03 will help patients.
Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength?
06:01am, Tuesday, 24'th Jan 2023
Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furth
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
08:30am, Tuesday, 25'th Oct 2022
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis
Positive d ata to be presented at WCC VIII and AAO 2022 conferences in Chicago
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Misses Revenue Estimates
06:49pm, Thursday, 11'th Aug 2022
Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of 63.08% and 8.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the st
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Misses Revenue Estimates
08:19pm, Tuesday, 10'th May 2022
Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of -12.64% and 90.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
04:33pm, Tuesday, 03'rd May 2022
Tarsus Pharmaceuticals, Inc. (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRVINE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr
7 Biotech Stocks to Buy With Key Catalysts for April
06:59am, Tuesday, 05'th Apr 2022
Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies bel
